C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom
On Feb. 24, 2024, C2N Diagnostics (C2N) announced the medical device registration from the United Kingdom’s Medicines and…
Biotechnology | Disease | FDA | Therapeutics
Swissmedic Authorises CSL’s HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
On Jan. 15, 2024, CSL announced that Swissmedic had authorised HEMGENIX® (etranacogene dezaparvovec), the first and currently only gene…
WHO announced influenza A(H1N2) variant virus infection in the Great Britain and Northern Ireland
On Dec. 1, 2023, the World Health Organization (WHO) announced that the International Health Regulations National Focal Point…
Vertex and CRISPR Therapeutics announced authorization of first CRISPR/Cas9 gene-edited therapy by UK MHRA for treatment of Sickle Cell Disease
On Nov. 16, 2023, Vertex and CRISPR Therapeutics announced that the United Kingdom (U.K.) Medicines and Healthcare products…
Novavax received full Marketing Authorization for potype COVID-19 vaccine Nuvaxovid in UK
On Oct. 18, 2023, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
Biotechnology | Disease | HIV | Influenza | Measles | Medicine | Plague | Polio | Therapeutics | Vaccine
The United Kingdom announced the Vaccine Development and Evaluation Centre
On Aug. 7, 2023, the United Kingdom Health and Security Agency announced the Vaccine Development and Evaluation Centre…
Agriculture | Biotechnology | Diagnostics | Infectious Disease | Influenza | Therapeutics | Vaccine | Veterinary
UK Animal and Plant Health Agency reported asymptomatic human detections of influenza A (H5N1)
On Jul. 14, 2023, the UK Animal and Plant Health Agency reported that additional asymptomatic human detections of…
WHO reported Avian influenza A(H5N1) in United Kingdom of Great Britain and Northern Ireland
On May 30, 2023, the United Kingdom of Great Britain and Northern Ireland reported to the World Health…
BioNTech announced strategic partnership with UK Government to provide up to 10,000 patients with personalized mRNA cancer immunotherapies
On Jan. 5, 2023, BioNTech announced that the Company had signed a Memorandum of Understanding with the Government…
Spanish, Italian and French Health Authorities expanded recommendations for use of Novavax COVID-19 vaccine
On Jan. 5, 2023, Novavax announced that Spain’s Public Health Commission, Italy’s Ministry of Health, and France’s Haute…
Moderna finalized strategic partnership with UK government
On Dec. 21, 2022, Moderna announced the the finalization of a strategic partnership with the United Kingdom (UK)…
Hutchinson Cancer Center leads large-scale review of COVID-19 clinical trials that highlights multiple disparities
On Dec. 5, 2022, the Fred Hutchinson Cancer Center announced that according to a new meta-analysis women were…
Novavax Nuvaxovid COVID-19 Vaccine authorized in the United Kingdom for use as a booster in adults
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
Study confirmed link between COVID-19 vaccination and temporary increase in menstrual cycle length
On Sept. 27, 2022, the National Institutes of Health (NIH) announced that a large international study had confirmed…
Novavax made one million doses of Nuvaxovid available for use in the United Kingdom
On Sept. 27, 2022, Novavax announced that an initial one million doses of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine were…
Novavax Nuvaxovid COVID-19 vaccine granted expanded conditional marketing authorization in UK for use in adolescents aged 12 through 17
On Aug. 26, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
Novavax filed in the UK for expanded conditional Marketing Authorization of COVID-19 vaccination booster in adult
On Jun. 2, 2022, Novavax announced the submission of a request to the Medicines and Healthcare products Regulatory…
Novavax participated in Oxford University Com-COV3 booster trial of COVID-19 vaccines in adolescents aged 12 through 15
On May 25, 2022, Novavax announced it was participating in a stage of the COVID-19 Vaccine Schedule Combinations…
Multi-country outbreak reported in Twelve member nations not endemic for Mpox Virus
On May 21, 2022, the World Health Organization (WHO) reported that since May 13, 2022, cases of mpox…
WHO informed of a confirmed case of monkeypox in an individual who travelled from the United Kingdom to Nigeria
On May 7, 2022, WHO was informed of a confirmed case of monkeypox in an individual who travelled…
Novavax announced extended durability of protection against infection and disease in UK COVID-19 vaccine phase 3 clinical Trial
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
Sanofi and GSK announced regulatory authorization for COVID-19 vaccine
On Feb. 23, 2022, Sanofi and GSK announced that they planned to submit data from both their booster…
UK MHRA granted Conditional Marketing Authorization for Novavax COVID-19 vaccine in Great Britain
On Feb. 3, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency had granted conditional marketing…
Novavax submitted request to U.S. FDA for Emergency Use Authorization of COVID-19 vaccine
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
Merck and Ridgeback announced supply agreement with UNICEF for molnupiravir, investigational oral antiviral COVID-19 medicine
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
DNA from air could revolutionize the way we measure animal biodiversity
On Jan. 6, 2022, two new studies published in the journal Current Biology showed that environmental DNA (eDNA)…
Merck and Ridgeback announced U.K. Government to purchase additional 1.75 million courses of molnupiravir
On Dec. 22, 2021, Merck and Ridgeback Biotherapeutics announced that the United Kingdom Government agreed to purchase an…
Moderna announced supply agreement with the UK for additional 60 million doses of COVID-19 vaccine in 2022 and 2023
On Dec. 1, 2021, Moderna announced a revised supply agreement with the UK government for up to 60…
Novavax filed for authorization of its COVID-19 vaccine in the United Kingdom
On Oct. 27, 2021, Novavax announced the completion of its rolling regulatory submission to the U.K. Medicines and…
Axcella Therapeutics launched clinical program to develop treatment for patients with long COVID
On Oct. 26, 2021, Axcella Therapeutics announced a new clinical program to investigate AXA1125 as a potential treatment…